(Alliance News) - AstraZeneca PLC on Thursday said a phase III trial involving its Lynparza medication did not meet its primary endpoint, though the drug maker insisted it is "committed to expanding its benefits".
The phase III GY004 trial looked to assess the efficacy of new medicine Cediranib when combined with Lynparza for patients with platinum-sensitive relapsed ovarian cancer, a disease where sufferers respond to medication which contains the precious metal.
AstraZeneca said the trial did not show "a significant improvement in progression-free survival" - which refers to the length of time a patient lives with the disease without it worsening - when compared to those treated with platinum-based chemotherapy.
Executive Vice President for Oncology Jose Baselga said: "Despite these disappointing results, we remain committed to expanding on the benefits already demonstrated with Lynparza for patients with advanced ovarian cancer."
It represent another trial blow for the FTSE 100 pharmaceutical firm. On Friday last week, it said its phase III Danube trial for bladder cancer treatments, Imfinzi and Imfinzi plus tremelimumab, also did not meet the primary endpoints.
Shares in the company were down 4.2% at 6,652.00 pence in London early Thursday.
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)